How The MDR Is Making The EU Competitively Backward
Executive Summary
Pedantic versus pragmatic implementation of the EU MDR and its guidances, as well as notified bodies struggling with capacity and new processes, are creating a clunky, slow and expensive EU regulatory system that could damage EU industry, delegates heard at the RAPS Convergence meeting earlier this week.
You may also be interested in...
Exec Chat: Ligence CFO Addresses The Challenges Faced By An Early-Stage AI Company
Medtech Insight spoke to the chief financial officer of Ligence, a Lithuanian start-up developing AI for echocardiography, to find out more about its commercial strategy, and problems it faces with commercialization.
EU Regulatory Round-Up, January 2023: Cautious Optimism As New MDR Proposal Unveiled
All eyes were on the European Commission in January as it edged closer to adopting new legislation that will see the Medical Device Regulation transition deadlines extended.
MDR Amendment Proposal Likely To Be Adopted In Two Weeks’ Time
Amending the MDR to stem the flow of medtech products being withdrawn from the market has long been seen as urgent. It looks like the EU is keeping its foot on the accelerator to adopt its latest proposal despite concerns raised about the text.